Drug Repurposing: Unlocking access to rare solutions
Express Pharma
NOVEMBER 1, 2024
The FDA’s 505(b)(2) pathway and the European Medicines Agency’s (EMA) Hybrid Pathway offer routes for drug developers to rely on previously submitted clinical data, cutting down approval times significantly. As the world’s largest manufacturer of generic medicines, India has vast potential to utilise repurposed drugs.
Let's personalize your content